Evidence map›Paper›PMID 35480981›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.

Agnes Bonifacius, Sabine Tischer-Zimmermann, Maria Michela Santamorena, Philip Mausberg, Josephine Schenk, Stephanie Koch, Johanna Barnstorf-Brandes, Nina Gödecke, Jörg Martens, Lilia Goudeva and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Agnes BonifaciusHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Sabine Tischer-ZimmermannHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Maria Michela SantamorenaHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Philip MausbergHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Josephine SchenkHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Stephanie KochDeutsche Gesellschaft für Gewebetransplantation, Hannover, Germany.
Johanna Barnstorf-BrandesHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Nina GödeckeHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Jörg MartensHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Lilia GoudevaHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Murielle VerboomHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Jana WittigDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Britta Maecker-KolhoffDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Herrad BaurmannMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Caren ClarkMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Olaf BraunsMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Martina SimonMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Peter LangDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Oliver A CornelyDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Michael HallekDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Rainer BlasczykHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Dominic SeiferlingMiltenyi Biomedicine GmbH, Bergisch Gladbach, Germany.
Philipp KöhlerDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Britta Eiz-VesperHannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
Medizinische Hochschule Hannover · DEMiltenyi Biotec (Germany) · DEUniversity Hospital Cologne · DEUniversity of Cologne · DEDeutsche Gesellschaft für Information und Wissen · DEUniversity Children's Hospital Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adoptive T cell therapyantiviral T cellsCOVID-19immunotherapySARS-CoV-2

Identifiers

PMID35480981
PMCPMC9036989
OpenAlexW4223618073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.